
    
      This is a randomized, double-blinded, dose escalating, phase Ia trial, which will be
      conducted in No. 302 Hospital of China. There are seven cohorts at dose of 0.21mg, 0.525mg,
      2.1mg, 4.2mg, 6.3mg, 8.4mg and 10.5mg. The first cohort with 0.21mg is an open test with no
      placebo as control. All other healthy volunteers will be randomized into Hepalatide or
      placebo group at 4:1 rate, and will be received drug by abdominal subcutaneous injection and
      will be observed for 8 days.
    
  